A double-blind study of functional outcomes with atomoxetine-hydrochloride and placebo in adult outpatients with DSM-IV attention-deficit/hyperactivity disorder
Latest Information Update: 11 Oct 2006
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 11 Oct 2006 New trial record.